StreetInsider.com News Articles

B.Riley Assumes Exagen (XGN) at Buy

Fri, 11 Sep 2026 08:49:22 -0400

B.Riley analyst Sergey Bolshakov assumes coverage on Exagen (NASDAQ: XGN) with a Buy rating and a price target of $12.00.

For an analyst ratings summary and ratings history on Exagen click here. For more ratings news on Exagen click here.

Shares of Exagen closed at $6.97 yesterday.

Form 4 EXAGEN INC. For: Jun 09 Filed by: Robertson Bruce C

Thu, 27 Aug 2026 17:54:00 -0400

si-local-file:///var/storage/secattach/20260827/26991480.html

Form 4 EXAGEN INC. For: Jun 09 Filed by: Robertson Bruce C

Thu, 27 Aug 2026 17:54:00 -0400

si-local-file:///var/storage/secattach/20260827/26991480.html

Form 4 EXAGEN INC. For: Jun 09 Filed by: Kim Paul

Thu, 27 Aug 2026 17:54:00 -0400

si-local-file:///var/storage/secattach/20260827/26991482.html

Form 4 EXAGEN INC. For: Jun 09 Filed by: Kim Paul

Thu, 27 Aug 2026 17:54:00 -0400

si-local-file:///var/storage/secattach/20260827/26991482.html

Form 4/A EXAGEN INC. For: Jun 09 Filed by: Robertson Bruce C

Mon, 24 Aug 2026 18:54:00 -0400

si-local-file:///var/storage/secattach/20260824/26969452.html

Form 4/A EXAGEN INC. For: Jun 09 Filed by: Robertson Bruce C

Mon, 24 Aug 2026 18:54:00 -0400

si-local-file:///var/storage/secattach/20260824/26969452.html

Form 4 EXAGEN INC. For: Jun 09 Filed by: Robertson Bruce C

Wed, 19 Aug 2026 18:58:00 -0400

si-local-file:///var/storage/secattach/20260819/26951499.html

Form 4 EXAGEN INC. For: Jun 09 Filed by: Robertson Bruce C

Wed, 19 Aug 2026 18:58:00 -0400

si-local-file:///var/storage/secattach/20260819/26951499.html

Form 4 EXAGEN INC. For: Jun 09 Filed by: Kim Paul

Wed, 19 Aug 2026 18:57:00 -0400

si-local-file:///var/storage/secattach/20260819/26951491.html

Form 4 EXAGEN INC. For: Jun 09 Filed by: Kim Paul

Wed, 19 Aug 2026 18:57:00 -0400

si-local-file:///var/storage/secattach/20260819/26951491.html

Exagen (XGN) PT Raised to $12 at B.Riley

Wed, 05 Aug 2026 08:38:16 -0400

B.Riley analyst Anderson Schock raised the price target on Exagen (NASDAQ: XGN) to $12.00 (from $8.00) while maintaining a Buy rating.

Exagen (XGN) PT Raised to $10 at TD Cowen

Wed, 05 Aug 2026 08:12:08 -0400

TD Cowen analyst Dan Brennan raised the price target on Exagen (NASDAQ: XGN) to $10.00 (from $8.00) while maintaining a Buy rating.

Exagen (XGN) PT Raised to $9 at Roth/MKM

Tue, 04 Aug 2026 12:57:51 -0400

Roth/MKM analyst Max Masucci raised the price target on Exagen (NASDAQ: XGN) to $9.00 (from $8.00) while maintaining a Buy rating.

Form 10-Q EXAGEN INC. For: Jun 30

Tue, 04 Aug 2026 09:16:00 -0400

si-local-file:///var/storage/secattach/20260804/26863117.html

Form 10-Q EXAGEN INC. For: Jun 30

Tue, 04 Aug 2026 09:16:00 -0400

si-local-file:///var/storage/secattach/20260804/26863117.html

Exagen Inc. (XGN) Tops Q2 EPS by 6c

Tue, 04 Aug 2026 08:25:28 -0400

Exagen Inc. (NASDAQ: XGN) reported Q2 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $19.94 million versus the consensus estimate of $17.81 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.

Form 8-K EXAGEN INC. For: Aug 04

Tue, 04 Aug 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260804/26862047.html

Form 8-K EXAGEN INC. For: Aug 04

Tue, 04 Aug 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260804/26862047.html

Exagen Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 08:00:00 -0400

Achieved record total revenue, test volume and trailing twelve-month ASP

Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million

Increased full-year revenue guidance to $72 - $75 million

CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2026, and recent corporate updates.

Exagen Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 08:00:00 -0400

Achieved record total revenue, test volume and trailing twelve-month ASP

Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million

Increased full-year revenue guidance to $72 - $75 million

Exagen Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 08:00:00 -0400

Achieved record total revenue, test volume and trailing twelve-month ASP

Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million

Increased full-year revenue guidance to $72 - $75 million

Exagen Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 08:00:00 -0400

Achieved record total revenue, test volume and trailing twelve-month ASP

Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million

Increased full-year revenue guidance to $72 - $75 million

Exagen Inc. to Participate in Upcoming Investor Conference

Tue, 28 Jul 2026 09:00:00 -0400

CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference:

Canaccord Genuity 46^th Annual Growth Conference – Boston, MA
Date: August 11, 2026
Fireside Chat at 8:30am ET
A live and archived webcast of the Fireside Chat will be available on Exagen’s Investor Relations website at investors.exagen.com.

About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based

Exagen Inc. to Participate in Upcoming Investor Conference

Tue, 28 Jul 2026 09:00:00 -0400

About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based